Ocular Adverse Events following Use of Immune Checkpoint Inhibitors for Metastatic Malignancies.
Carl W NobleSapna S GangaputraIan A ThompsonAmy YuanAndrea B ApoloJung-Min LeeGeorge N PapaliodisShilpa KodatiRachel BishopM Teresa MagoneLucia SobrinH Nida SenPublished in: Ocular immunology and inflammation (2019)
We found a wide spectrum of ocular irAEs associated with immune checkpoint inhibitors. In most cases, ocular AEs did not limit ongoing cancer treatment.